The One Thing To Settle Before Buying AbbVie Stock
Alpha Vantage · Trefis · · AI-summarised by FinFlash
AbbVie's stock trades at a higher multiple than the S&P 500, with its adjusted earnings multiple around 21 based on 2026 forecasts. The key factor for investors is whether its double-digit sales growth can continue, especially with a government-set price taking effect on its drug Vraylar in 2027.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.